Related Experiment Video
Updated: Sep 13, 2025
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
EFTX-G12V: a novel KRASG12V-selective RNAi therapeutic
Kostas A Papavassiliou1, Alice G Vassiliou2, Athanasios G Papavassiliou3
1First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
Abstract:
KRASG12V-driven cancers remain therapeutically elusive. Recently, Stanland and colleagues developed EFTX-G12V, a GE11-conjugated small interfering RNA (siRNA) that selectively silences KRASG12V and achieves tumor regression by inhibiting oncogenic signaling and angiogenesis and enhancing anti-tumor immunity. EFTX-G12V represents an innovative RNAi-based precision oncology strategy for previously undruggable oncogenic mutations.
Insights
Stanland and colleagues developed EFTX-G12V, a novel small interfering RNA (siRNA) therapy. This therapy selectively silences KRASG12V, leading to tumor regression and offering a new strategy for previously untreatable cancers.
Area of Science:
- Oncology
- Molecular Biology
- RNA Therapeutics
Background:
- KRASG12V mutations drive numerous cancers, presenting significant therapeutic challenges.
- Targeting KRASG12V has historically been difficult, leaving a critical unmet need in precision oncology.
Purpose of the Study:
- To develop and evaluate EFTX-G12V, a novel RNA interference (RNAi) therapeutic agent.
- To assess the efficacy of EFTX-G12V in silencing KRASG12V and inducing tumor regression.
Main Methods:
- Development of GE11-conjugated small interfering RNA (siRNA) named EFTX-G12V.
- Administration of EFTX-G12V to target KRASG12V-driven tumors.
- Evaluation of tumor regression, oncogenic signaling inhibition, angiogenesis modulation, and anti-tumor immunity enhancement.
Main Results:
- EFTX-G12V selectively silenced the KRASG12V oncogene.
- Treatment with EFTX-G12V resulted in significant tumor regression.
- The therapy demonstrated inhibition of oncogenic signaling and angiogenesis.
- EFTX-G12V enhanced the anti-tumor immune response.
Conclusions:
- EFTX-G12V is a promising RNAi-based precision oncology strategy.
- This approach offers a potential therapeutic option for cancers driven by KRASG12V mutations.
- EFTX-G12V represents a breakthrough for previously undruggable oncogenic mutations.
